FTSE 100 news / Companies and sectors / AstraZeneca
AstraZeneca news analysis
AstraZeneca (LSE: AZN) is in the FTSE 100. 21 of the last 21 days had relevant coverage.
Latest: Tuesday 20 October 2026
+5.5 from 24 relevant stories. Coverage was mostly positive, centred on the Oracle AI partnership and four Phase III trials being presented at ESMO, with supportive analyst targets. Small negatives were a patent dispute with Pharmacor, a withdrawn EU prostate cancer filing and a weaker share price.
Tone over time
Coverage of AstraZeneca improved between 30 September 2026 and 20 October 2026
Daily news tone, from −10 (clearly bad) to +10 (clearly good). Gaps are days with no relevant stories.
Tone rose 65% from 3 to 6 between 30 Sep and 20 Oct. Its low was 0 in 12 Oct.
- 11
- 22
- 33
1 day of 21 had fewer than 3 relevant stories, so that point is thin evidence. Numbered markers are the days with the strongest single headline (key below). This is the tone of coverage, not a share price.Source: MarketFrame news analysis
| day | Tone |
|---|---|
| 30 Sep | 3 |
| 1 Oct | 7 |
| 2 Oct | 2 |
| 3 Oct | 6 |
| 4 Oct | 4 |
| 5 Oct | 5 |
| 6 Oct | 7 |
| 7 Oct | 8 |
| 8 Oct | 7 |
| 9 Oct | 7 |
| 10 Oct | 2 |
| 11 Oct | 7 |
| 12 Oct | 0 |
| 13 Oct | 2 |
| 14 Oct | 5 |
| 15 Oct | 8 |
| 16 Oct | 6 |
| 17 Oct | 6 |
| 18 Oct | 6 |
| 19 Oct | 4 |
| 20 Oct | 6 |
Day by day
| Day | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Tuesday 20 October 2026 | +5.5 | 24 | Coverage was mostly positive, centred on the Oracle AI partnership and four Phase III trials being presented at ESMO, with supportive analyst targets. |
| Monday 19 October 2026 | +4.0 | 3 | Coverage was light, centred on a preview of AstraZeneca's investor event and news that its asthma, RSV and cancer drugs received PBAC approval. |
| Sunday 18 October 2026 | +5.7 | 6 | Coverage was mainly about AstraZeneca opening a new corporate office in Mumbai and announcing a new collaboration with insitro. |
| Saturday 17 October 2026 | +6.3 | 32 | Coverage was dominated by the AI drug discovery deal with insitro, alongside supportive analyst targets and ratings from RBC, Berenberg and Citi, plus expansion news from its Indian arm. |
| Friday 16 October 2026 | +5.7 | 38 | Coverage was dominated by AstraZeneca's AI drug discovery partnership with insitro, worth up to about $1.5 billion and focused on MASH and cardiomyopathies. |
| Thursday 15 October 2026 | +7.5 | 30 | Coverage centred on a sharp share price rise, with upgrades, higher price targets and oncology deals cited. |
| Wednesday 14 October 2026 | +5.0 | 10 | Coverage was mostly positive, with a new $1 billion R&D hub, a Saudi approval for Baxfendy, a $2 billion deal and supportive analyst ratings. |
| Tuesday 13 October 2026 | +1.7 | 23 | Coverage was split between the failed Phase III efzimfotase alfa trial in hypophosphatasia, which weighed on tone, and positive items such as the Summit investment, a new US R&D centre, Citi's peak sales view and COPD data. |
| Monday 12 October 2026 | −0.3 | 8 | Coverage was split between disappointing trial news, with ALXN1850 missing statistical significance and efzimfotase alfa missing its primary endpoint, and more positive stories about the $2 billion Summit investment and AI drug discovery. |
| Sunday 11 October 2026 | +7.0 | 2 | Coverage was mainly about AstraZeneca's new AI tie-up for its biologics labs and a senior hire in solid tumour cell therapy. |
| Saturday 10 October 2026 | +2.0 | 9 | Coverage centred on the Summit Therapeutics investment and a CE mark for a companion diagnostic tied to AstraZeneca's breast cancer drug. |
| Friday 9 October 2026 | +7.0 | 15 | Coverage was mostly positive, led by EU approvals for Trixeo in asthma and a camizestrant companion diagnostic, a China approval for a breast cancer drug, and a Jefferies Buy rating. |
| Thursday 8 October 2026 | +6.7 | 27 | Coverage was mostly positive, centred on the new $1bn Massachusetts R&D centre, the Summit Therapeutics collaboration and analyst support from Jefferies, Citi and Berenberg ahead of third-quarter results. |
| Wednesday 7 October 2026 | +7.8 | 36 | Coverage was dominated by the opening of AstraZeneca's $1bn R&D hub in Massachusetts, alongside Citi's higher price target on strong clinical data and the completed $2bn Summit investment. |
| Tuesday 6 October 2026 | +6.8 | 37 | Coverage was dominated by the opening of AstraZeneca's $1bn R&D centre in Cambridge, Massachusetts, with hiring plans. |
| Monday 5 October 2026 | +4.5 | 11 | Coverage was mostly positive on pipeline news, including faster FDA review of a bladder cancer regimen, positive phase 3 COPD results and an Indian panel nod for camizestrant. |
| Sunday 4 October 2026 | +3.7 | 4 | Coverage mostly centred on AstraZeneca's tie-up with Summit Therapeutics and Daiichi Sankyo to test a cancer drug combination, which leans positive. |
| Saturday 3 October 2026 | +6.0 | 34 | Coverage was dominated by AstraZeneca's $2bn investment in Summit Therapeutics and a clinical collaboration with Daiichi Sankyo to test Datroway with ivonescimab, which was framed positively for its oncology pipeline. |
| Friday 2 October 2026 | +1.7 | 17 | Coverage was dominated by AstraZeneca's $2 billion investment in Summit Therapeutics and related cancer trial collaborations, which brought a small share price dip. |
| Thursday 1 October 2026 | +7.0 | 20 | Coverage centred on AstraZeneca's $2bn investment in Summit Therapeutics for cancer drug collaboration, which brokers praised and which saw the shares lead FTSE 100 healthcare higher. |
| Wednesday 30 September 2026 | +3.3 | 35 | Coverage was dominated by AstraZeneca's $2 billion equity investment in Summit Therapeutics, which was widely seen as a strategic oncology move and drew supportive analyst comment. |
Sector: Pharma and healthcare